IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · In This Article: IGMS. – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –. – IGM-2644 ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and …
5 days ago · IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire 1d IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M
IGM Biosciences Announces Third Quarter 2024 Financial Results …
Sep 30, 2024 · IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 ...
News - IGM Biosciences
Aug 14, 2024 · News. MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare. – …
IGM Biosciences' New Found Focus: Pivots From Cancer To …
Oct 1, 2024 · On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for...
IGM Biosciences Announces Strategic Pivot to Focus Exclusively …
Sep 30, 2024 · IGMS. – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial …
Jan 9, 2023 · IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development. – Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients –. – Encouraging safety profile in combination with FOLFIRI chemotherapy –. – Randomized combination trial ...
Home - IGM Biosciences
6 days ago · Make an impact at IGM. Help us bring a new class of antibody medicines to patients. » LEARN MORE ABOUT BEING PART OF THE IGM TEAM. Recent News. November 8, 2024. IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update. November 4, 2024.
- Some results have been removed